ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
International Journal of Medicinal Mushrooms
インパクトファクター: 1.423 5年インパクトファクター: 1.525 SJR: 0.433 SNIP: 0.661 CiteScore™: 1.38

ISSN 印刷: 1521-9437
ISSN オンライン: 1940-4344

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v13.i5.10
pages 401-426

Medicinal Mushrooms for Glycemic Control in Diabetes Mellitus: History, Current Status, Future Perspectives, and Unsolved Problems (Review)

Hui-Chen Lo
Department of Nutritional Science, Fu Jen Catholic University, New Taipei City, Taiwan
Solomon P. Wasser
N.G. Kholodny Institute of Botany, NAS of Ukraine, 2 Tereshchenkovskaya Str., Kiev 01004, Ukraine; International Center for Cryptogamic Plants and Fungi, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel

要約

Diabetes mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia with defects in insulin secretion and/or insulin resistance. Despite great efforts that have been made in the understanding and management of diabetes, its prevalence continues to grow. Recent discoveries have opened up an exciting opportunity for developing new types of therapeutics from medicinal mushrooms to control DM and its complications. To date, more and more active components including polysaccharides and their protein complexes, dietary fibers, and other compounds extracted from fruiting bodies, cultured mycelium, or cultured broth of medicinal mushrooms have been reported as to having anti-hyperglycemic activity. These compounds exhibit their antidiabetic activity via different mechanisms. This article presents an overview of the multiple aspects of diabetes mellitus and the efficacy and mechanism of medicinal mushrooms for glucose control in diabetes, including the inhibition of glucose absorption, protection of beta-cell damage, increase of insulin release, enhancement of antioxidant defense, attenuation of inflammation, modulation of carbohydrate metabolism pathway, and regulation of insulin-dependent and insulin-independent signaling pathways. However, there is insufficient evidence to draw definitive conclusions about the efficacy of individual medicinal mushrooms for diabetes. In addition, the wide variability, the lack of standards for production, and the lack of testing protocols to assess product quality are still problems in producing medicinal mushroom products. Moreover, well-designed randomized controlled trials with long-term consumption are needed to guarantee the bioactivity and safety of medicinal mushroom products for diabetic patients.


Articles with similar content:

Gene Therapy in Type 1 Diabetes
Critical Reviews™ in Immunology, Vol.28, 2008, issue 4
John Iacomini, Chaorui Tian, Jesus Paez-Cortez, Jessamyn Bagley
Clinical Trials for Medicinal Mushrooms: Experience with Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Lingzhi Mushroom)
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 1&2
Yihuai Gao, Eli Chan, Shufeng Zhou
The Need for Scientific Validation of Culinary-Medicinal Mushroom Products
International Journal of Medicinal Mushrooms, Vol.8, 2006, issue 2
Shu-Ting Chang
An Overview of Culinary and Medicinal Mushrooms in Neurodegeneration and Neurotrauma Research
International Journal of Medicinal Mushrooms, Vol.19, 2017, issue 3
Chai-Chee Ng, Kah-Hui Wong, Gowri Kanagasabapathy, Yoon-Yen Yow, Vikineswary Sabaratnam
Current and Future Research Trends in Agricultural and Biomedical Applications of Medicinal Mushrooms and Mushroom Products (Review)
International Journal of Medicinal Mushrooms, Vol.20, 2018, issue 12
Shu Ting Chang, Solomon P. Wasser